Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns
Pfizer shares rose 0.3% to $25.36 after a U.S. appeals court blocked a Trump-era pilot that would have changed drug payments for safety-net hospitals. The ruling affects drugs like Eliquis, co-marketed by Pfizer and Bristol Myers Squibb. Investors await Pfizer CEO Albert Bourla’s update at the J.P. Morgan Healthcare Conference on Jan. 12. Pfizer reports earnings Feb. 3, with COVID sales and patent losses in focus.